Related references
Note: Only part of the references are listed.Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
Matthias Klinger et al.
CANCER RESEARCH (2020)
How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy
Ibrahim Aldoss et al.
BLOOD (2020)
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
Emily Y. Jen et al.
CLINICAL CANCER RESEARCH (2019)
Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation
Brice Mouttet et al.
HAEMATOLOGICA (2019)
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Elias J. Jabbour et al.
CANCER (2019)
Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia
Herve Dombret et al.
LEUKEMIA & LYMPHOMA (2019)
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
Amber C. King et al.
LEUKEMIA RESEARCH (2019)
A FIRST-IN-HUMAN STUDY OF A HALF-LIFE EXTENDED CD19-TARGETING BiTE IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA OR FOLLICULAR LYMPHOMA
L. Popplewell et al.
HEMATOLOGICAL ONCOLOGY (2019)
Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies
Roman H. Khadka et al.
IMMUNOTHERAPY (2019)
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study
Elias J. Jabbour et al.
CANCER (2019)
Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma
Deborah A. Katz et al.
BLOOD (2019)
A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331
Patrick A. Brown et al.
BLOOD (2019)
Mechanisms of failure of chimeric antigen receptor T-cell therapy
Xiaoqing Li et al.
CURRENT OPINION IN HEMATOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Anthony Stein et al.
DRUG SAFETY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany
Lukas Mayerhoff et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2019)
Chimeric Antigen Receptor-Natural Killer Cells: The Future of Cancer Immunotherapy
Sana Habib et al.
OCHSNER JOURNAL (2019)
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
Julio C. Chavez et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
Max S. Topp et al.
BLOOD (2018)
Bispecific antibodies in haematological malignancies
Andreas Viardot et al.
CANCER TREATMENT REVIEWS (2018)
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
David Porter et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
Colin E. Correnti et al.
LEUKEMIA (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia
E. Dianne Pulte et al.
ONCOLOGIST (2018)
CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment
Clare Y. Slaney et al.
CANCER DISCOVERY (2018)
Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage
Elias Jabbour et al.
CANCER (2018)
Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial
Koji Sasaki et al.
BLOOD (2018)
Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study
Jonathan Webster et al.
BLOOD (2018)
Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
Anjali S. Advani et al.
BLOOD (2018)
Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Luke Coyle et al.
BLOOD (2018)
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia
Anthony S. Stein et al.
BLOOD ADVANCES (2018)
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
Tania Jain et al.
BLOOD ADVANCES (2018)
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
Nitin Jain et al.
BLOOD (2017)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
Jeannette Fischer et al.
JOURNAL OF IMMUNOTHERAPY (2017)
High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
J. Pan et al.
LEUKEMIA (2017)
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
J. Duell et al.
LEUKEMIA (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement
Annabelle Zoghbi et al.
PEDIATRIC BLOOD & CANCER (2017)
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
E. Mejstrikova et al.
BLOOD CANCER JOURNAL (2017)
Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective
Thomas E. Delea et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation
Monika Brueggemann et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
Rita Assi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Cytokine release syndrome: Who is at risk and how to treat
Noelle Frey
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
Philadelphia chromosome-like acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2017)
Inotuzumab Ozogamicin: First Global Approval
Yvette N. Lamb
DRUGS (2017)
Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia
Ibrahim Aldoss et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment
T. Yuraszeck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
A. Viardot et al.
BLOOD (2016)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy
Ahmad Rayes et al.
PEDIATRIC BLOOD & CANCER (2016)
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Elad Jacoby et al.
NATURE COMMUNICATIONS (2016)
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
N. Goekbuget et al.
BLOOD CANCER JOURNAL (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
Judith Feucht et al.
ONCOTARGET (2016)
Treatment of older patients with acute lymphoblastic leukemia
Nicola Goekbuget
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
Noelle V. Frey et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
Kum Ja Lee et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Marco Ruella et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2016)
Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation
Daniel W. Lee et al.
BLOOD (2016)
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
Elias Jabbour et al.
CANCER (2015)
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
Thomas Koehnke et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Acute Lymphoblastic Leukemia in Children
Stephen P. Hunger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Chimeric antigen receptor T-cell therapy for ALL
Shannon L. Maude et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
t(17;19) in Children with Acute Lymphocytic Leukemia: A Report of 3 Cases and a Review of the Literature
Katherine A. Minson et al.
CASE REPORTS IN HEMATOLOGY (2013)
How I treat relapsed childhood acute lymphoblastic leukemia
Franco Locatelli et al.
BLOOD (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding et al.
BLOOD (2007)
Share Paper
